Promising cancer treatment has this one firing

September 16, 2024 *sponsored by Stock Earnings Good day, 360! Here are our top investing ideas today. And don’t forget to join us in [Market Masters]( - the hottest trading room around 🔥. Be the best prepared trader on the Street! FOCUS LIST🔎 NCNA - Up over 180% in pre after presenting encouraging Melanoma treatment data at ESMO Congress 2024 ADAG- Up over 13% in pre after presenting positive results in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) treatment at ESMO Congress 2024 ZNTL - Up over 36% in pre after announcing FDA has lifted partial clinical hold on Azenosertib Studies  *sponsored by Stock Earnings Gold’s Booming, But These Gold Stocks are Doing Even Better Physical gold protects your wealth, but miners are where the real action is. Here are 10 gold stocks in particular to watch… [Claim your free report now]( HOTLIST🔥 NCNA - Up over 180% in pre after presenting encouraging Melanoma treatment data at ESMO Congress 2024 NuCana plc (NCNA) is a clinical-stage biopharmaceutical company that engages in the development of medicines to treat patients with cancer. Over the weekend, the [company presented]( final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy. In this cohort of 12 patients, most of whom had received at least two prior lines of PD-1 inhibitor therapy, nine (75%) achieved disease control, including two patients who achieved Partial Responses. One of these patients, who had received two prior lines of PD-1 inhibitor-based therapy and had progressed on their latest treatment of ipilimumab plus nivolumab within two months, achieved a 55% reduction in tumor volume. Seven of the 12 patients had a progression free survival time of greater than five months, which is highly atypical in this patient population. In addition to achieving these encouraging efficacy signals, the combination of NUC-7738 and pembrolizumab had a favorable safety profile. The stock traded up over 180% in the pre-market in reaction to the positive results. The first target for bulls is the prior resistance area at $7.96. Above that the pre-market high at $9.69 comes into play. Beyond that, targets to the upside are $10.79, $12 and $20. Below $7.96, targets to the downside are $7, $6.58, $5, $4.30, $3.30 and then a gap fill at $2.54. ADAG- Up over 13% in pre after presenting positive results in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) treatment at ESMO Congress 2024 Adagene Inc. (ADAG) is a clinical stage biotechnology company that engages in the research, development, and production of monoclonal antibody drugs for cancers. Over the weekend, the [company announced]( new ADG126 clinical data presented at the ESMO Congress, taking place in Barcelona, Spain, September 13-17. Highlights include: - Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab - - Median progression-free survival of 8.5 months observed in patients without liver and peritoneal metastases at the ADG126 10 mg/kg Q3W dose - - At the 10 mg/kg dose level, 12-month overall survival (OS) rates were 74% for patients without liver metastases, and 82% for those without liver and peritoneal metastases - - Safety profile maintained, with only 16% Grade 3 TRAEs in patients treated with ADG126 10 mg/kg Q3W in combination with pembrolizumab - - Combination shows potential with standard of care to address broader patient populations, including MSS CRC patients with liver metastases - The stock traded up over 13% in the pre-market in reaction to the positive news. The first target for bulls is the pre-market high at $4.01. Beyond that, $4.30, $5, and $5.75 come into play. Below $4.01, targets to the downside are $3.80, $3.60 and then a gap fill at $3.49 with $3 below that. Are you in Bullseye Trades yet? If not… you missed DJT for the WIN! *Trading is hard, results not guaranteed and should not be expected to be replicated typically. Get My Top Trade Weekly [Next One Drops Monday Morning!]( Live Bullseye Session at 11AM EST in Market Masters ZNTL - Up over 36% in pre after announcing FDA has lifted partial clinical hold on Azenosertib Studies  Zentalis Pharmaceuticals Inc. (ZNTL) is a clinical-stage biopharmaceutical company that focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. In the pre-market this morning, the [company announced]( that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on studies of Azenosertib, the Company’s novel, selective, and orally bioavailable inhibitor of WEE1. The FDA has cleared the company to resume enrollment in all ongoing Azenosertib clinical studies with no changes in the clinical development plan. Zentalis will be working with clinical trial investigators to resume study activities across the Azenosertib development program as quickly as possible. The Company remains on track to meet all previously disclosed data guidance for the remainder of 2024. The stock traded up over 36% in the pre-market in reaction to the news. The first target for bulls is the pre-market high at $4.84. Beyond that, $5.47, $5.70, $6.40 and $8.39 come into play. Below $4.84, targets to the downside are $4.16, $4, $3.80, $3.60 and then a gap fill at $3.24. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [( *Sponsored content: We’re a proud affiliate for Stock Earnings, meaning if you click a link for a product or service, we may earn a commission at no extra cost to you. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](